MedTrace Logo

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

NCT06505551 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-07-17

No results posted yet for this study

Summary

This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited to combination chemotherapy and/or combination chemo-immunotherapy

Conditions

  • HPV-Related Squamous Cell Carcinoma
  • HPV-Related Cervical Squamous Cell Carcinoma
  • HPV-Related Vulvar Squamous Cell Carcinoma
  • HPV-Related Penile Squamous Cell Carcinoma
  • HPV-Related Vaginal Squamous Cell Carcinoma
  • HPV-Related Anal Squamous Cell Carcinoma
  • HPV-Related Head and Neck Cancer

Interventions

BIOLOGICAL

SCG142

Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy

DRUG

Cyclophosphamide

for 3 consecutive days

DRUG

Fludarabine

for 3 consecutive days

Sponsors & Collaborators

  • SCG Cell Therapy Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • SCG Cell Therapy · SCG Cell Therapy Pte. Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2026-12-31
Completion
2028-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06505551 on ClinicalTrials.gov